This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Geisler, J. Articles by Lønning, P. E. Search for Related Content PubMed PubMed Citation Articles by Geisler, J. Articles by Lønning, P. E. Related Collections Clinical Research Clinical Research: Clinical Pharmacology

Aromatase Inhibition: Translation into a Successful Therapeutic Approach

Authors' Affiliation: Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergen, Norway

Requests for reprints: Per Eystein Lønning, Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergen, Norway. Phone: 47-55-97-2010; Fax: 47-55-97-2046; E-mail: per.lonning{at}helse-bergen.no.

The development of the novel third-generation aromatase inhibitors and inactivators for breast cancer treatment is one of the most successful contemporary achievements in cancer therapy. Parallel to studies evaluating toxicity and clinical efficacy in metastatic disease, the endocrine effects of multiple compounds were evaluated, leading to the identification of the highly potent third-generation aromatase inhibitors based on estrogen deprivation and aromatase inhibition in vivo. Thus, translational studies have been of vital importance identifying the unique characteristics of these compounds. Whereas first- and second-generation aromatase inhibitors inhibit estrogen synthesis in vivo by up to 90%, the third-generation compounds anastrozole, exemestane, and letrozole were found to cause 98% aromatase inhibition. This article summarizes and discusses the "translational research" that provided the background for the implementation of the third-generation aromatase inhibitors and inactivators into large clinical trials. The need for future translational research exploiting the mechanisms of resistance to these compounds for future improvement of endocrine therapy is emphasized.

Key Words: Aromatase inhibitors • Breast cancer • Translational research • Estrogens

This article has been cited by other articles:

				D. I. Shulman, G. L. Francis, M. R. Palmert, E. A. Eugster, and for the Lawson Wilkins Pediatric Endocrine Society Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development Pediatrics, April 1, 2008; 121(4): e975 - e983. [Abstract] [Full Text] [PDF]

				R. Ponzone, P. Mininanni, E. Cassina, F. Pastorino, and P. Sismondi Aromatase inhibitors for breast cancer: different structures, same effects? Endocr. Relat. Cancer, March 1, 2008; 15(1): 27 - 36. [Abstract] [Full Text] [PDF]

				G. Hudelist, K. Czerwenka, J. Keckstein, C. Haas, A. Fink-Retter, D. Gschwantler-Kaulich, E. Kubista, and C.F. Singer Expression of Aromatase and Estrogen Sulfotransferase in Eutopic and Ectopic Endometrium: Evidence for Unbalanced Estradiol Production in Endometriosis Reproductive Sciences, December 1, 2007; 14(8): 798 - 805. [Abstract] [PDF]